Your institution may have access to this item. Find your institution then sign in to continue.
Title
Exenatide for once-weekly administration.
Abstract
▾Exenatide is a glucagon-like peptide 1 (GLP-1) agonist used in the management of people with type 2 diabetes. A twice-daily injectable formulation (▾Byetta - Eli Lilly) was licensed in 2006. ▾Bydureon (Eli Lilly) is a prolonged-release injectable formulation that allows once-weekly administration. Here we discuss the place of Bydureon in the management of type 2 diabetes mellitus.
Publication
Drug and therapeutics bulletin, 2012, Vol 50, Issue 7, p78